TABLE 2.
Rates of antimicrobial resistance among isolates collected in this study and comparison with JANIS data
| Antimicrobial agent(s) | % of isolates collected in this study resistant among: |
% of Acinetobacter species isolates resistant (no. of isolates tested) in JANIS annual report 2013b | |||
|---|---|---|---|---|---|
| IC II (n = 245a) | Non-IC II (n = 400) | Non-baumannii (n = 221) | All isolates (n = 866) | ||
| Piperacillin-tazobactam | 24.5 | 0.8 | 0.9 | 7.5 | 7.8 (4,953) |
| Ampicillin-sulbactam | 8.2 | 0.0 | 0.0 | 2.3 | 5.8 (4,498) |
| Ceftazidime | 69.8 | 2.0 | 0.9 | 20.9 | 10.0 (20,856) |
| Cefepime | 48.2 | 4.0 | 0.0 | 15.5 | 9.2 (15,394) |
| Imipenem | 3.7 | 1.3 | 0.0 | 1.6 | 3.6 (16,947) |
| Meropenem | 4.9 | 1.3 | 0.0 | 2.0 | 3.7 (17,027) |
| Gentamicin | 51.0 | 6.0 | 2.7 | 17.9 | 9.5 (19,422) |
| Amikacin | 24.5 | 0.0 | 0.0 | 6.9 | 3.5 (20,863) |
| Levofloxacin | 87.8 | 13.0 | 2.7 | 31.5 | 8.3 (20,040) |
| Ciprofloxacin | 100 | 24.8 | 6.8 | 41.5 | No data |
| Minocycline | 13.5 | 0.0 | 0.0 | 3.8 | No data |
| Colistin | 0.0 | 0.3 | 1.8 | 0.6 | No data |
| Polymyxin B | 0.0 | 0.0 | 0.9 | 0.2 | No data |